Delivery Order SPE2DB20D1109-SPE2DB25FP50G
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $25,932.24 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes. This competitively awarded, firm fixed-price contract is scheduled for completion by August 21, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,440.70 for XOLAIR 150 mg/mL syringes, with an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract representing a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 75 mg/0.5 ml syringes with a ceiling value of $1,080.54 and a firm fixed price structure. This delivery order is non-set-aside and represents a competitively awarded contract with an ultimate completion date of August 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes, valued at $2,161.02, with an ultimate completion date of August 22, 2025. This contract was awarded on August 1, 2025, under a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a $2,881.36 delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes, with an ultimate completion date of August 13, 2025. This firm fixed price contract, awarded July 23, 2025, represents a non-set-aside competitive award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of XOLAIR 300 mg/2 mL auto-injector vials with a ceiling value of $1,594.16 and firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,644.16 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 15, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the DLA supply...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order for XOLAIR 150 mg/ml syringes valued at $108,051.00 under a firm fixed-price contract. This non-set-aside award was issued on July 31, 2025, with an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. XOLAIR is a biologic medication used to treat moderate-to-severe allergic asthma and other...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $21,610.20 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on July 28, 2025, with an ultimate completion date of August 18, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location in the same municipality. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Xolair (omalizumab) 150 mg/mL syringes, valued at $28,813.60 with a firm fixed price contract type. This award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The contract was competitively awarded with no...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP50GDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,800.90 to AmerisourceBergen Drug Corp for the supply of XOLAIR 75 mg/0.5 ml syringes. This competitively awarded, firm fixed-price delivery order was established on August 1, 2025, with an ultimate completion date of August 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor agreement running through December 2026 that encompasses pharmaceutical products and medical supplies for military healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, regularly fulfills federal medical procurement requirements through open competition and maintains no set-aside designation on this award. The company's extensive portfolio with DLA includes delivery of diverse pharmaceutical products spanning multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies. This delivery order for XOLAIR—a biologic medication commonly used for severe asthma and other allergic conditions—reflects the company's ongoing role as a critical vendor supporting military and veteran healthcare systems through flexible contract vehicles designed to meet global pharmaceutical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/1/25 |